SXTP vs GERN vs IMVT vs AEYE

For growth investors, 60 Degrees Pharmaceuticals, Inc.

(SXTP) is the stronger pick with 139. 6% revenue growth year-over-year, versus 14. 5% for AudioEye, Inc. (AEYE). Analysts rate Geron Corporation (GERN) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -99. 4% for 60 Degrees Pharmaceuticals, Inc. (SXTP). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SXTP's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Immunovant, Inc.

(IMVT) is the lower-risk stock at 1. 37β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 67% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 111% for Geron Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), 60 Degrees Pharmaceuticals, Inc.

(SXTP) is pulling ahead at 139. 6% versus 14. 5% for AudioEye, Inc. (AEYE). On earnings-per-share growth, the picture is similar: Geron Corporation grew EPS 51. 9% year-over-year, compared to -1852. 6% for 60 Degrees Pharmaceuticals, Inc.. Over a 3-year CAGR, GERN leads at 575. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -1308. 0% for 60 Degrees Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -1599. 0% for SXTP. At the gross margin level — before operating expenses — GERN leads at 97. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immunovant, Inc.

(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). 60 Degrees Pharmaceuticals, Inc. (SXTP) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, SXTP: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SXTP (Healthcare) and GERN (Healthcare) and IMVT (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SXTP is a small-cap high-growth stock; GERN is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.